Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion

PACE - Pacing and Clinical Electrophysiology

Volumn 31, Issue 8, 2008, Pages 1036-1040

  Xia, Wei ^a   Qu, Xiufen ^a,c   Yu, Yang ^a   Zhang, Xueli ^b   Feng, Wei ^a   Song, Ying ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Atrial fibrillation; Cardioversion; Recurrence

Indexed keywords

ARGININE DERIVATIVE; DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVERSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE;

AGED; ARGININE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 48249093448     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.01131.x     Document Type: Article

References (34)

1. Falk RH. Atrial fibrillation. N Engl J Med 2001 344 : 1067 1078.
2. Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, Van Der Woude HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998 31 : 167 173.
3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997 96 : 1180 1184.
4. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS, Tsang TS, et al. High sensitivity C-reactive protein: A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005 46 : 1284 1287.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992 339 : 572 575.
6. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006 58 : 159 178.
7. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 1999 99 : 1141 1146.
8. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethylarginine in children and young adults with hypertension: A basis for atheroma? Blood Press 2000 9 : 16 21.
9. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998 98 : 1842 1847.
10. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation 2003 108 : 933 938.
11. Abbasi F, Asagmi T, Cooke JP, Lamendola C, Mclaughlin T, Reaven GM, Stuehlinger M, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001 88 : 1201 1203.
12. Szuba A, Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor-evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006 58 (Suppl 16 20.
13. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Nephrol 2006 17 : 2176 2183.
14. Smith CL. C-reactive protein and asymmetric dimethylarginine: Markers or mediators in cardiovascular disorders? Curr Pharm Des 2007 13 : 1619 1629.
15. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 2002 106 : 2854 2858.
16. Cengel A, Sahinarslan A, Biberoglu G, Hasanoglu A, Tavil Y, Ozdemir M. Asymmetrical dimethylarginine levels in acute onset and chronic atrial fibrillation. Available at : http://www.egms.de/en/meetings/ice2006/06ice120. shtml, 20-03-2008/08-02-2007.
17. Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006 29 : 559 563.
18. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001 104 : 2886 2891.
19. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991 88 : 4651 4655.
20. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996 78 : 225 230.
21. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 2002 106 : 873 879.
22. Van Wagoner DR. Electrophysiological remodeling in human atrial fibrillation. Pacing Clin Electrophysiol 2003 26 : 1572 1575.
23. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: The potential role of inflammation and oxidative stress. Med Sci Monit 2003 9 : 225 229.
24. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007 115 : 135 143.
25. Cooke JP. Asymmetrical dimethylarginine: The uber marker? Circulation 2004 109 : 1813 1819.
26. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001 89 : E32 E38.
27. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: An insight into the pathophysiological significance of raised plasma ADMA. PLoS Med 2005 2 : 264.
28. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004 24 : 1682 1688.
29. Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin system: A therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 2006 29 : 1006 1012.
30. Murray KT, Mace LC, Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 2007 4 (Suppl.3 88 90.
31. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001 158 : 425 430.
32. Wanby P, Teerlink T, Brudin L, Brattström L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006 185 : 271 277.
33. Osanai T, Nakamura M, Sasaki S, Tomita H, Saitoh M, Osawa H, Yamabe H, et al. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Kidney Int 2003 64 : 2291 2297.
34. Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hiltmeyer N, Haddad M, et al. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 2007 35 : 1876 1881.